Can carboplatin or etoposide replace actinomycin-d for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia?
-
Add time:08/14/2019 Source:sciencedirect.com
ObjectiveTo evaluate the impact of periodic shortage of actinomycin-d (Act-d) in the treatment of Brazilian patients with low-risk gestational trophoblastic neoplasia (GTN) after methotrexate and folinic acid rescue (MTX/FA) resistance, treated alternately with carboplatin or etoposide as a second-line regimen.
We also recommend Trading Suppliers and Manufacturers of actinomycin K (cas 11011-00-0). Pls Click Website Link as below: cas 11011-00-0 suppliers
Prev:On the mode of action of Edeine (cas 11006-90-9): II. Studies on the binding of Edeine (cas 11006-90-9) to Escherichia coli ribosomes
Next:Modeling improved production of the chemotherapeutic polypeptide actinomycin D by a novel Streptomyces sp. strain from a Saharan soil) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Actinomycin D, cisplatin, and etoposide regimen is associated with almost universal cure in patients with high-risk gestational trophoblastic neoplasia☆08/19/2019
- Coordination ability of silver(I) with antimycins and actinomycins – Properties of the T-shaped chromophores08/18/2019
- Structural aspects of the interaction of anticancer drug Actinomycin-D to the GC rich region of hmgb1 gene08/17/2019
- Purification and identification of an actinomycin D analogue from actinomycetes associated with Ganoderma applanatum via magnetic molecularly imprinted polymers and tandem mass spectrometry08/16/2019
- Modeling improved production of the chemotherapeutic polypeptide actinomycin D by a novel Streptomyces sp. strain from a Saharan soil08/15/2019
-
Health and Chemical more >